Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03243422 · ClinicalTrials.gov registry record · NA

Aging and Cognitive Health Evaluation in Elders (ACHIEVE)

A NA study, sponsored by Johns Hopkins Bloomberg School of Public Health.

Completed
Registry status
NA
Development phase
977
Enrollment target

NCT03243422: Completed NA study, sponsored by Johns Hopkins Bloomberg School of Public Health.

NCT03243422 is a NA study that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 977 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03243422, a NA study, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.

COMPLETED
Registry status
NA
Development phase
977 participants
Enrollment target

Study Summary

The ACHIEVE study will be a randomized controlled trial nested within the infrastructure of the Atherosclerosis Risk in Communities (ARIC) study. We plan to enroll 850 70-84 year-old cognitively normal older adults with hearing loss, who will be randomized 1:1 to the hearing intervention (hearing needs assessment, fitting of hearing devices, education/counseling) or successful aging health education intervention (individual sessions with a health educator covering healthy aging topics). Post-baseline, participants will be followed semi-annually for 3 years.

Primary Outcome

Mean change in global cognitive function in standard deviations from baseline to year 3 estimated from a linear mixed-effects model. Global cognitive function was defined as a factor score derived from the completion of a neurocognitive testing battery. The ACHIEVE study administers a neurocognitive testing battery annually, which includes the following cognitive tests: Delayed Word Recall, Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Word List, Incidental Learning, Logical

Interventions

  • OTHER Hearing intervention
  • OTHER Successful aging health education intervention

Trial Details

FieldValue
Enrollment Target 977 participants
Start Date 2018-01-04
Est. Completion 2023-06-12
Phase NA

What the finished NCT03243422 record still lists

NCT03243422 is an interventional study that assigns participants to a tested intervention. The registered 977 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (30% lower).

The record links to 0 conditions, and to 2 interventions - of which Hearing intervention is the first listed.

NCT03243422 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03243422 about?

NCT03243422 is a clinical study titled "Aging and Cognitive Health Evaluation in Elders (ACHIEVE)". The ACHIEVE study will be a randomized controlled trial nested within the infrastructure of the Atherosclerosis Risk in Communities (ARIC) study. We plan to enroll 850 70-84 year-old cognitively normal older adults with hearing loss, who will be randomized 1:1 to the hearing intervention (hearing ne...

What is the current status of trial NCT03243422?

This trial is currently completed. It is a NA study. The enrollment target is 977 participants. The study started on 2018-01-04. Estimated completion is 2023-06-12.

What interventions are being tested in trial NCT03243422?

The interventions under investigation include: Hearing intervention (OTHER), Successful aging health education intervention (OTHER).

Who is sponsoring clinical trial NCT03243422?

This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03243422's enrollment target sits among peer trials

977 122nd of 2000 higher than 1,879 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06988306 · 978 participants · NA

    Lifestyle Interventions to Prevent Diabetes in U.S. Home Visiting Programs

  • NCT05600777 · 975 participants · Phase 3

    A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

  • NCT06541704 · 975 participants · Phase 3

    A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  • NCT06820736 · 975 participants · NA

    A Prospective, Randomized Comparison Of Drainage Techniques After One- Or Two-Level Open Posterior Lumbar Decompression Or Decompression And Fusion

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03243422, the US trial registry maintained by the National Library of Medicine. NCT03243422 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.